Share on StockTwits

Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost bought 30,000 shares of the company’s stock in a transaction that occurred on Thursday, August 28th. The shares were purchased at an average cost of $8.84 per share, with a total value of $265,200.00. Following the purchase, the chief executive officer now directly owns 2,012,377 shares of the company’s stock, valued at approximately $17,789,413. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

A number of research firms have recently commented on OPK. Analysts at Jefferies Group reiterated a “buy” rating on shares of Opko Health in a research note on Wednesday, August 13th. They now have a $10.50 price target on the stock, down previously from $11.00. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $12.00.

Shares of Opko Health (NYSE:OPK) traded up 0.85% on Friday, hitting $8.935. The stock had a trading volume of 557,999 shares. Opko Health has a 1-year low of $7.32 and a 1-year high of $12.95. The stock’s 50-day moving average is $8.93 and its 200-day moving average is $8.87. The company’s market cap is $3.835 billion.

Opko Health (NYSE:OPK) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.03. The company had revenue of $23.50 million for the quarter, compared to the consensus estimate of $23.70 million. During the same quarter in the previous year, the company posted ($0.01) earnings per share. The company’s revenue for the quarter was down 1.3% on a year-over-year basis. Analysts expect that Opko Health will post $-0.31 EPS for the current fiscal year.

OPKO Health, Inc (NYSE:OPK) is a multi-national biopharmaceutical and diagnostics company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.